Why the study?
Malignant tumors induce metabolic disorders and energy imbalance affecting the myocardium, and tumor-produced substances directly impact cardiomyocyte metabolism and life cycle.
This review highlights the direct detrimental effects of tumor-related factors and oncogenes on the myocardium, contributing to cardiovascular pathology in oncology patients.
Alerts clinicians to tumor-related myocardial risks in oncology; leaves open targeted cardioprotection research.
The myocardium, which has a high metabolic activity, responds to metabolic disorders and energy imbalance induced by a growing malignant tumor. In addition, the tumor itself can produce substances that directly affect metabolic processes and the life cycle of cells not involved in the neoplastic process, including cardiomyocytes. This review summarized and systematized current data on individual aspects of detrimental effects of oncogenes and tumor-related factors on the heart muscle and morpho-functional changes in the cardiovascular system of oncology patients. Also, the authors described in detail development of these pathogenetic mechanisms.
No takes yet. Share an insight, caveat, or question.
Обрезан et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: